NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
Natural Alternatives International Inc. NAII
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$129.9M
▲ 14.1% vs FY2023
EPS · FY24
$-2.28
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-18.0%
Net margin · FY24
-10.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 129.9M
Revenue, FY2024 · full 15-year series below
Revenue
Net income
The company lost 10 cents on every revenue dollar this year.
Per share
USD -2.28
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-18.0%
Return on equity, FY2024
ROE
Operating margin-6.7%
Net margin-10.5%
Return on assets-8.6%
Each USD of equity lost 18 cents this year.
Returned to shareholders
USD 178,000.00
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 178,000.00
Share of profit-1.3%
Consecutive raises—
USD 178,000.00 in buybacks went back to shareholders in a year without profit.
Growth
+1.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−8.8%
+1.8%
+5.0%
Returned to shareholders
−68.1%
−45.6%
−21.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years−8.5%
Change, 10 years−8.4%
The share count shrank 9% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 151.9M
total assets, end of FY2024
Total assetsUSD 151.9M
EquityUSD 68.4M
CashUSD 12.3M
Current ratio2.06×
Equity funds 45% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Operating income $B
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−2.28
−1.23
0.43
1.74
1.69
−0.25
0.92
0.73
1.09
1.44
0.49
0.29
0.23
0.59
0.71
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−18.0
−8.4
2.8
12.7
14.2
−2.2
9.1
7.8
12.6
19.6
7.8
4.8
3.9
11.0
14.3
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
60 of 60
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed